Janet, Genentech just about completed a 100+ patient Herceptin-DM1 trial, it was conducted at 40 some sites and recruited from MBC patients that had progressed on Herceptin. Company sounds very excited about results they seen so far. A new phase II is scheduled to start this month, an additional inclusion item is that candidates have been exposed to Tykerb and/or Xeloda.
Side effects from drug are minimal! Mention the trial to your oncologist.
Here's a link that will give you further information.
http://www.clinicaltrials.gov/ct2/sh...erm=dm1&rank=3